Komori
PRISM BioLab (206A) · RiskWorsenedLatest Financial results briefing materials (2026-05-18): "Mitigated"

Liquidity and Additional Financing Risks from Continued Upfront Investment

First written in FY2024. 2 of 4 entries say "Worsened", first in FY2025. Latest entry: 2026-05-18.

4entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024WorsenedFY2025 – 2026-05-142024: 12025: 120252026: 22026
Same theme, other companies
Funding and Liquidity Risk from Ongoing Investment and Negative Operating Cash FlowA theme 7 companies write about · 7 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 3 of 7 companies on the "Worse" side.

1 other company's latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Moved together

"Strengthening the Financial Base to Support Upfront Investments" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222★123
  1. ★This thread
  2. 1Strengthening the Financial Base to Support Upfront Investments2×
  3. 2Risk of Discontinuation of the Company’s In-House Research and Development Program Materializes2×
  4. 3Dilution of Share Value Through Share Acquisition Rights and Capital Increases2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PRISM BioLab yet. It last moved in the Financial results briefing materials of 2026-05-18: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.